Caxmotabart Entudotin

N/A

Report date: 2025/05/06 11:11:52

Base Information

Drug NameCaxmotabart Entudotin
Drug Alias NameTrastuzumab monomethyl auristatin FFS-1502LCB14-0110LCB-14-0110IKS014 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > β-glucuronide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAF payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionAnti-HER2Tubulin inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeNew Zealand +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLegochembio
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesIksuda Therapeutics IncIksuda TherapeuticsShanghai Fosun Pharmaceutical Industrial Development Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[5] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A